TN-201

Business news, market intelligence, and global industry analysis.

The Latest

Could subcutaneous PD-1 therapy reshape oncology treatment logistics in China?

Cargo theft is rising across North America. Can Eagle Vision Security’s iFM platform stop it before it starts?

The hidden problem with GLP-1 weight loss and Veru Inc.’s bet to fix it (NASDAQ: VERU)

GRPN slides after Q4 revenue shortfall raises questions about Groupon’s turnaround durability

Tenaya Therapeutics’ TN-201 gene therapy shows early success in treating MYBPC3 hypertrophic cardiomyopathy

Discover how Tenaya Therapeutics’ TN-201 gene therapy is showing early signs of transforming treatment for MYBPC3-associated HCM—read more on the trial details and outlook.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

November 8, 2025